Johnson & Johnson (NYSE:JNJ) Stock Price Up 1.6% Following Analyst Upgrade

Johnson & Johnson (NYSE:JNJ)’s share price rose 1.6% during mid-day trading on Monday after HSBC raised their price target on the stock from $240.00 to $265.00. HSBC currently has a buy rating on the stock. Johnson & Johnson traded as high as $231.19 and last traded at $230.82. Approximately 8,178,718 shares changed hands during trading, a decline of 13% from the average daily volume of 9,386,169 shares. The stock had previously closed at $227.25.

Other equities analysts also recently issued research reports about the stock. Argus increased their price objective on shares of Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Citigroup raised their price objective on Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Finally, UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $233.05.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently bought and sold shares of JNJ. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $26,000. DecisionPoint Financial LLC grew its position in Johnson & Johnson by 104.2% in the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares during the period. Clayton Financial Group LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at $28,000. Family CFO Inc bought a new position in Johnson & Johnson in the 4th quarter valued at about $31,000. Finally, Evolution Wealth Management Inc. bought a new position in Johnson & Johnson in the 2nd quarter valued at about $27,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The business has a 50 day simple moving average of $210.72 and a 200-day simple moving average of $191.76. The firm has a market cap of $556.11 billion, a price-to-earnings ratio of 20.89, a P/E/G ratio of 2.21 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company had revenue of $24.56 billion for the quarter, compared to analyst estimates of $24.14 billion. During the same quarter last year, the company earned $2.04 earnings per share. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.